Terms: = Head and neck cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Staging
10 results:
1. Relationship between Trace Elements and Matrix Metalloproteinases 2 and 9 and their Tissue Inhibitors in Medullary Thyroid Carcinoma.
Vázquez-Lorente H; Dundjerović DM; Tatić SB; Rodríguez-Menéndez S; González-Iglesias H; Gomes CM; Paunović IR; Dragutinović VV
Biol Trace Elem Res; 2023 Jul; 201(7):3225-3232. PubMed ID: 36156766
[TBL] [Abstract] [Full Text] [Related]
2. Animal model and bioinformatics analyses suggest the timp1/MMP9 axis as a potential biomarker in oral squamous cell carcinoma.
Xu G; Wei J; Huangfu B; Gao J; Wang X; Xiao L; Xuan R; Chen Z; Song G
Mol Carcinog; 2020 Nov; 59(11):1302-1316. PubMed ID: 33006223
[TBL] [Abstract] [Full Text] [Related]
3. Identification of key genes and miRNAs markers of papillary thyroid cancer.
Qiu J; Zhang W; Zang C; Liu X; Liu F; Ge R; Sun Y; Xia Q
Biol Res; 2018 Nov; 51(1):45. PubMed ID: 30414611
[TBL] [Abstract] [Full Text] [Related]
4. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients.
Groblewska M; Mroczko B; Kozlowski M; Niklinski J; Laudanski J; Szmitkowski M
Folia Histochem Cytobiol; 2012; 50(4):590-8. PubMed ID: 23264224
[TBL] [Abstract] [Full Text] [Related]
5. Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
El Badry AA; El-Fadle AA; El-Balshy AL
MedGenMed; 2007 Jul; 9(3):3. PubMed ID: 18092010
[TBL] [Abstract] [Full Text] [Related]
6. [Progress of clinical pathology and application of PET-CT on thyroid carcinoma].
Gao M; Li XL; Yu Y; Sun BC; Li SL; Xu WG
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Jun; 41(6):419-24. PubMed ID: 16927796
[TBL] [Abstract] [Full Text] [Related]
7. RT-PCR expression profiling of matrix metalloproteinases and their specific inhibitors in cell lines and fresh biopsies of squamous cell carcinomas of the head and neck.
Dünne AA; Mandic R; Falkenberg S; Dalchow CV; Sesterhenn AM; Werner JA
In Vivo; 2005; 19(5):943-8. PubMed ID: 16097450
[TBL] [Abstract] [Full Text] [Related]
8. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
[TBL] [Abstract] [Full Text] [Related]
9. Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma.
Schmalbach CE; Chepeha DB; Giordano TJ; Rubin MA; Teknos TN; Bradford CR; Wolf GT; Kuick R; Misek DE; Trask DK; Hanash S
Arch Otolaryngol Head Neck Surg; 2004 Mar; 130(3):295-302. PubMed ID: 15023835
[TBL] [Abstract] [Full Text] [Related]
10. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract] [Full Text] [Related]
